Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Sandmann

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Science Translational Medicine|June 5, 2024
Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degenerationMarvin Reich, Matthew J Simon, Beate Polke, et al.
Neuron|January 7, 2020
TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic ChallengeAlicia A Nugent, Karin Lin, Bettina van Lengerich, et al.
Nature Communications|February 20, 2025
Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistributionNathalie Khoury, Michelle E Pizzo, Claire B Discenza, et al.
The Journal of Prevention of Alzheimer'S Disease|December 1, 2025
Towards an AI biomedical scientist: Accelerating discoveries in neurodegenerative diseaseKaleigh F Roberts, Eric C Landsness, Justin Reese, et al.
Nature Communications|April 15, 2026
Author Correction: Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistributionNathalie Khoury, Michelle E Pizzo, Claire B Discenza, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 28, 2023
The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in IndiaShan V Andrews, Prashanth L Kukkle, Ramesh Menon, et al.
Elife|September 17, 2024
DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress responseErnie Yulyaningsih, Jung H Suh, Melania Fanok, et al.
Cell|November 12, 2024
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomesJing L Guo, Dylan Braun, Gabriel A Fitzgerald, et al.
Science Translational Medicine|May 29, 2020
Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in miceJulie C Ullman, Annie Arguello, Jennifer A Getz, et al.
Nature Communications|August 18, 2025
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trialBrittany N Flores, Seungyoon B Yu, Isaac V Cohen, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Science Translational Medicine|June 5, 2024
Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degenerationMarvin Reich, Matthew J Simon, Beate Polke, et al.
Neuron|January 7, 2020
TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic ChallengeAlicia A Nugent, Karin Lin, Bettina van Lengerich, et al.
Nature Communications|February 20, 2025
Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistributionNathalie Khoury, Michelle E Pizzo, Claire B Discenza, et al.
The Journal of Prevention of Alzheimer'S Disease|December 1, 2025
Towards an AI biomedical scientist: Accelerating discoveries in neurodegenerative diseaseKaleigh F Roberts, Eric C Landsness, Justin Reese, et al.
Nature Communications|April 15, 2026
Author Correction: Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistributionNathalie Khoury, Michelle E Pizzo, Claire B Discenza, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 28, 2023
The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in IndiaShan V Andrews, Prashanth L Kukkle, Ramesh Menon, et al.
Elife|September 17, 2024
DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress responseErnie Yulyaningsih, Jung H Suh, Melania Fanok, et al.
Cell|November 12, 2024
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomesJing L Guo, Dylan Braun, Gabriel A Fitzgerald, et al.
Science Translational Medicine|May 29, 2020
Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in miceJulie C Ullman, Annie Arguello, Jennifer A Getz, et al.
Nature Communications|August 18, 2025
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trialBrittany N Flores, Seungyoon B Yu, Isaac V Cohen, et al.
Pageof 5